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Edited by Beat ImhofAbstract Peroxisomeproliferator-activated receptorc (PPARc)
ligands have been shown to inhibit the eﬀects of proinﬂammatory
cytokines such as interleukin-1b (IL-1b). This cytokine plays a key
role in articular pathophysiologies by inducing the production of
inﬂammatorymediators such as nitric oxide (NO) and prostaglan-
din E2 (PGE2). We previously demonstrated that 15d-PGJ2 was
more potent than troglitazone to counteract IL-1b eﬀects on
chondrocytes. Here, we studied the action of 15d-PGJ2 on
intracellular targets in nuclear factor-jB (NF-jB) signalling
pathway in IL-1b treated rat chondrocytes. We found that 15d-
PGJ2 decreased inhibitor jBa (IjBa) degradation but not its
phosphorylation by speciﬁcally inhibiting IjBkinase b (IKKb), but
not IKKa, enzymatic activity. We further evaluated the involve-
ment of PPARc in the anti-inﬂammatory action of its ligands. In
chondrocytes overexpressing functional PPARc protein, 15d-
PGJ2 pre-treatment inhibited inducible NO synthase and COX-2
mRNAexpression, nitrite andPGE2 production, p65 translocation
andNF-jBactivation. Troglitazone or rosiglitazone pre-treatment
had no eﬀect. 15d-PGJ2 exhibited the same eﬀect in chondrocytes
overexpressingmutatedPPARc protein. These results suggest that
15d-PGJ2 exerts its anti-inﬂammatory eﬀect in rat chondrocytes
by a PPARc-independent mechanism, which can be conferred to a
partial inhibition of IjBa degradation.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Articular joint degradation is a common feature of rheu-
matoid arthritis and osteoarthritis. Proinﬂammatory cyto-
kines, such as interleukin-1 b (IL-1b), have been shown to
inhibit the synthesis of cartilage matrix proteins and to pro-
mote their degradation by activating metalloproteases [1,2]. In
addition, IL-1b induces the production of inﬂammatory me-
diators, such as nitric oxide (NO), prostaglandins and other
reactive oxygen species [3]. Therefore, the modulation of IL-1b
eﬀects and/or its production is known to be an important key
to counteract the cartilage degradation.
Peroxisome proliferator-activated receptor c (PPARc) is a
ligand-activated nuclear transcription factor belonging to the
nuclear receptor superfamily. PPARc heterodimerizes with
retinoid X receptor and binds to peroxisome proliferator re-
sponse element located in the promoter of PPARc target
genes. Agonists of PPARc include synthetic compounds, such
as thiazolidinediones, and natural compounds such as fatty
acids and 15-deoxy-D12;14-prostaglandin J2 (15d-PGJ2).
PPARc ligands are best characterized as regulators of adipo-
cyte diﬀerentiation, fatty acids storage and glucose homeo-
stasis [4–6]. Moreover, it has been suggested that PPARc
ligands have a role in the inﬂammation control by inhibiting
the transcriptional induction of genes such as TNF-a, induc-
ible NO synthase (iNOS) and gelatinase B in murine macro-
phages [7,8]. Interestingly, other studies showed that these
ligands could inhibit the production of TNFa, IL-1 and IL-6
by activated human monocytes [9].
In addition, in IL-1b stimulated chondrocyte cultures, we
and others recently showed that 15d-PGJ2 modulated NO and
prostaglandin production, as well as expression of proinﬂam-
matory genes [10–13]. These PPARc ligands inhibit gene ex-
pression in part by antagonizing the activities of transcription
factors such as nuclear factor-jB (NF-jB) and activating
protein-1 (AP-1) [9,14]. Other works suggested PPARc inde-
pendent mechanisms for the anti-inﬂammatory eﬀect of 15d-
PGJ2 by interacting with NF-jB signalling pathway [15–17].
Two main mechanisms were described in several cell lines
to explain the 15d-PGJ2 inhibitory eﬀects. Firstly, by inter-
acting with a cysteine residue in the DNA-binding domain of
the NF-jB subunit p65 [18]. Secondly, 15d-PGJ2 was shown
to block IjB kinase (IKK) activity, possibly through covalentblished by Elsevier B.V. All rights reserved.
34 S. Boyault et al. / FEBS Letters 572 (2004) 33–40modiﬁcations of critical cysteine residues in IKKb [15,16].
However, controversy still exists about the identiﬁcation of
intracellular targets involved in the mechanism of action of
15d-PGJ2. Moreover, the involvement of PPARc appears to
be strongly dependent on the cell type and very few data exist
in chondrocytes.
Following our previous published work [10], the aim of the
present study was to identify intracellular targets of 15d-PGJ2
in the NF-jB transcriptional pathway in rat chondrocytes. The
involvement of the nuclear receptor in 15d-PGJ2 action was
thereafter evaluated in chondrocytes transfected with a domi-
nant-negative PPARc vector and by comparing the action of
three PPARc ligands.
Our results showed that this cyclopentenone speciﬁcally
decreased IKKb activity without aﬀecting IKKa. This action
leads to the inhibition of inhibitor jBa (IjBa) degradation
without any modiﬁcation of its phosphorylation state. Fi-
nally, we found that 15d-PGJ2 signiﬁcantly inhibited IL-1b
eﬀects in chondrocytes transfected either with a PPARc-ex-
pression vector or with a dominant-negative PPARc vector.
This strongly suggests that 15d-PGJ2 exerts its anti-inﬂam-
matory action in chondrocytes by a PPARc-independent
mechanism.2. Materials and methods
2.1. Isolation and culture of rat chondrocytes
Chondrocytes were isolated from femoral head caps of Wistar male
rats by sequential digestion with pronase and collagenase B (Roche,
Meylan, France) as described previously [19]. The cells were cultured
to conﬂuence in 75-cm2 ﬂasks at 37 C in a humidiﬁed atmosphere
containing 5% CO2. The complete medium used was Dulbecco’s
modiﬁed Eagle’s medium/Ham’s F-12 supplemented with L-glutamine
(2 mM), penicillin (100 U/ml), streptomycin (100 lg/ml) and heat-in-
activated fetal calf serum (10%, Invitrogen, Cergy Pontoise, France).
Chondrocytes were used from the ﬁrst to the third passage.
2.2. Plasmids and transient transfection experiments
The pcDNA3.1 PPARc expression vector was generously provided
by Pr Johanne Martel-Pelletier (University of Montreal, Hopital Notre
Dame, Montreal, Canada). The pSG5 dominant negative PPARc
vector was a gift from Pr Marie Therese Corvol (Unite INSERM 530,
Universite de Paris 5, Paris, France).
Twenty-four hours before transfection, chondrocytes were seeded in
6-well plates at 5 105 cells /well and grown to 60–80% of conﬂuency.
Cells were transfected with 500 ng of a PPARc expression vector or
with 500 ng of dominant negative PPARc vector. The transfection was
performed using 10 ll of polyethylenimine reagent (Euromedex,
Souﬀelweyersheim, France) in 1 ml of complete medium. Two hours
later, the reagent containing medium was replaced by complete me-
dium. After a 36 h incubation, cells were treated with IL-1b in the
presence or absence of PPARc ligands.Table 1
Primers used for real-time quantitative RT-PCR and product length
Gene Primer sequence
INOS Sense 50-AATGCGGAAGGTCATGGC-30
Antisense 50-CGACTTTCCTGTCTCAGTAGCAAA-30
COX-2 Sense 50-TACAAGCAGTGGCAAAGGCC-30
Antinense 50-CAGTATTGAGGAGAACAGATGGG-30
RP29 Sense 50-AAGATGGGTCACCAGCAGCTCTACTG-30
Antisense 50-AGACGCGGCAAGAGCGAGAA-30
PS, product size in base pair and Tm, melting temperature.2.3. Recombinant rat IL-1b treatments in the presence of PPARc
ligands
Chondrocytes were incubated with a PPARc ligand or the vehicle
(0.1% dimethylsulfoxide (DMSO) in ﬁnal concentration) 1 h before the
addition of IL-1b (10 ng/ml, Sigma, St. Quentin Fallavier, France).
Cells were treated with IL-1b for 6 h (iNOS, cyclooxygenase-2 (COX-
2), RP29 mRNA analysis), for 30 min (NF-jB activation study), for 5
min (IjB and IKK phosphorylation studies) or for 24 h (NO and
prostaglandin E2 (PGE2) production measurements) in the presence of
the ligand. The PPARc ligands tested were troglitazone (Tro), rosig-
litazone (Rosi, 10 lM, Laboratoires Servier, Suresnes, France) and
15d-PGJ2 (10 lM, Calbiochem, Meudon, France). The three ligands
were found to be ineﬀective at 1 lM on the parameters tested, whereas
they were highly toxic for the cells at 100 lM.
2.4. RNA extraction and real-time PCR analysis
Total RNA was extracted from cell cultures by a single-step guan-
idinium thiocyanate–phenol–chloroform method using Trizol reagent
(Invitrogen). Two micrograms of total RNA was reverse transcribed
using hexa-nucleotides random primers. To quantify iNOS and COX-2
mRNA expression, real-time quantitative RT-PCR was performed
using Lightcycler Technology (Roche). The sequences for the primers
and product length are shown in Table 1. PCR was performed with
SYBRgreen master mix system (Qiagen, Courtaboeuf, France). Melt-
ing curve was performed to determine the melting temperature of the
speciﬁc PCR products. Each run included positive and negative con-
trols. To standardize iNOS and COX-2 mRNA concentrations, tran-
script levels of the housekeeping gene RP29 were determined in parallel
for each sample.
2.5. Quantiﬁcation of NO and PGE2 production
Thirty-six hours after transfection, chondrocyte cultures were trea-
ted as described before. NO production was measured as the amount
of nitrite (NO2 ) and nitrate (NO

3 ) levels (stable NO endproducts)
released into the culture medium using a spectroﬂuorimetric assay with
2,3-diaminonaphthalene (DAN) as reagent (Sigma), as previously de-
scribed [20,21]. Nitrate was previously converted to nitrite by the ac-
tion of nitrate reductase from Aspergillus niger (Roche).
The concentrations of PGE2 in culture medium were determined by
EIA kit (Oxford Biomedical Research, Oxford, USA) according to the
manufacturer’s instructions.
2.6. Nuclear proteins extraction and NF-jB transactivation analysis
Nuclear protein extracts were prepared with the TransAM nuclear
extract kit according to the manufacturer’s protocol (Active Motif
Europe, Rixensart, Belgium). Brieﬂy, cells were scraped into phos-
phate-buﬀered saline (PBS) with phosphatase and protease inhibitors,
centrifuged, resuspended in 1 hypotonic buﬀer and kept on ice for 15
min. After addition of detergent, the lysates were centrifuged at
14 000g for 30 s. The pellets were resuspended in complete lysis buﬀer
(20 mM HEPES, pH 7.5, 350 mM NaCl, 20% glycerol, 1% Igepal
CA630, 1 mM MgCl2, 0.5 mM ethylene diaminetetraacetic (EDTA),
0.1 mM ethylene glycol-O,O0-bis-[2-amino-ethyl]-N,N,N0,N0,-tetraace-
tic acid (EGTA), 1 mM DTT, phosphatase and protease inhibitors)
and vortexed. After incubation on ice and centrifugation, the super-
natants were collected and protein concentration was determined by a
Bradford-based assay (Bio-rad Laboratories).
NF-jB activation was determined by the TransAM ELISA kit
(Active Motif Europe). This assay based on a colorimetric reaction isTm (C) PS (pb) Cycle number
60 65 –
60 301 –
59 67 –
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containing an NF-jB consensus binding site has been immobilized in
each well of a 96-well plate. 5 lg of nuclear extract was added per well
and incubated for 1 h with middle agitation. The wells were then
washed three times with washing buﬀer (100 mM phosphate buﬀer, pH
7.5, 500 mM NaCl, and 1% Tween 20) and incubated with p65 anti-
body (1:1000 in washing buﬀer) for 1 h at room temperature. The wells
were ﬁnally incubated for 1 h with diluted horseradish peroxidase
(HRP)-conjugated antibody (1:1000 in washing buﬀer) before the ad-
dition of 100 ll of developing solution (3,30,5,50 tetramethylbenzidine
substrate solution diluted in 1% of DMSO) and a 5 min incubation.
The reaction was stopped by addition of 0.5 M H2SO4 solution. Ab-
sorbance was read on a spectrophotometer at 450 nm.
Cells were washed two times with ice-cold PBS and scrapped oﬀ the
ﬂask in cold lysis buﬀer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophos-
phate, 1 mM b-glycerophosphate, 1 mM Na3VO4, 1 mg/ml leupeptin
and 1 mM phenylmethyl sulphonyl ﬂuoride). Cells were disrupted by
sonication and centrifuged at 3000 rpm for 10 min. The supernatants
were collected and the protein concentration was determined by a
Bradford-based assay. Protein samples were analyzed by SDS/PAGE
and electroblotted onto polyvinylidene ﬂuoride membrane. After 1 h in
blocking buﬀer (5% non-fat dried milk in TBSTween 0.1%), mem-
branes were blotted overnight at 4 C with antibodies against phos-
phorylated IjBa, phosphorylated IKKa=b (Ozyme, St. Quentin en
Yvelines, France), IjBa, PPARc and b-actin (Sigma) for total proteinFig. 1. Inhibition by PPARc ligands of IL-1b induced iNOS (A) and COX
transiently transfected with a PPARc expression vector before being treated w
Total RNA was extracted and was analyzed for iNOS (A) and COX-2 (B)
pressed as relative arbitrary units (n ¼ 3; #P < 0:05, ##P < 0:01 vs. control;extracts (dilution 1:500 for all antibodies) and p65 (dilution 1:500;
Santa Cruz, USA) for nuclear extracts. After 3 washings with TBS-
Tween, the blot was incubated with anti-rabbit IgG conjugated with
HRP (Cell signaling, St. Quentin en Yvelines, France) at 1:2000 dilu-
tion in blocking buﬀer for 1 h at room temperature. Proteins were
detected by the Phototope chemiluminescence detection system (Cell
signaling).
2.7. Statistical analysis
After comparison of data by analysis of variance, the diﬀerent
groups were compared using Fisher’s t test. Assays were made in
triplicate (n ¼ 3) and P values (vs. control or IL-1b treatment) less
than 0.05 were considered signiﬁcant.3. Results
3.1. Modulation of IL-1b-induced iNOS and COX-2 mRNA
expression and nitrite and PGE2 production by PPARc
ligands
Preliminary experiments using Trypan blue and MTT
showed no modiﬁcation of cell viability and proliferation in rat
chondrocytes treated with IL-1b (10 ng/ml) and/or PPARc-2 (B) mRNA expression in rat chondrocytes. Rat chondrocytes were
ith IL-1b for 6 h in the presence or absence of PPARc ligands (10 lM).
mRNA expression by real-time quantitative RT-PCR. Results are ex-
P < 0:05 vs. IL-1b treatment).
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expression vector as described before. Thirty-six hours later,
the cultures were pre-incubated for 1 h in the presence of
PPARc ligands before being stimulated with IL-1b (10 ng/ml)
for 6 h (iNOS and COX-2 mRNA expression) or for 24 h (NO
and PGE2 production). IL-1b treatment induced a strong
iNOS (Fig. 1A) and COX-2 (Fig. 1B) mRNA expression. 15d-
PGJ2 pre-incubation led to a 90% (P < 0:05) decrease in IL-1b
induced iNOS mRNA expression and to a 52% (P < 0:05)
decrease in IL-1b induced COX-2 mRNA expression. In
contrast, Tro and Rosi pre-incubation did not modulate in-
duction of iNOS and COX-2 mRNA by IL-1b treatment.
Moreover, IL-1b treatment induced a strong production of
nitrites (57 lM) and PGE2 (2.52 ng/ml) by chondrocytes. 15d-
PGJ2 pre-incubation led to a 97% decrease (P < 0:01, 1.7 lM)
in nitrite production and a 63% decrease (P < 0:01, 0.94 ng/ml)
in PGE2 production (Fig. 2A and B). These results were co-
herent with its eﬀect on iNOS and COX-2 mRNA expression.
In contrast to the results obtained by iNOS and COX-2
mRNA expression, Tro slightly but signiﬁcantly reduced ni-PG
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again, the cyclopentenone prostaglandin alone induced an in-
crease in PGE2 production.
3.3. Eﬀect of PPARc ligands on NF-jB signalling pathway: p65
translocation and DNA binding activity
We ﬁrstly examined the eﬀects of 15d-PGJ2, Tro and Rosi
on p65 subunit translocation in nuclei of rat chondrocytes
treated with IL-1b (Fig. 4A). IL-1b treatment for 30 min in-
duced an important translocation of p65 in the nucleus. We
found that 15d-PGJ2 pre-incubation partially inhibited p65
translocation in the nucleus ()43%, P < 0:05). In contrast, Tro
or Rosi pre-incubation did not modulate IL-1b-induced p65
translocation in the nucleus.
We thereafter studied the eﬀect of the ligands on NF-jB
activation by measuring its DNA binding activity. NF-jB was
strongly activated by IL-1b (Fig. 4B). A pre-incubation with
Tro or Rosi led to no change on NF-jB activation. However,
15d-PGJ2 induced a 55% decrease (P < 0:05) in NF-jB DNA
binding activity. No signiﬁcant change in NF-jB activation
and p65 translocation was observed in cells incubated with
PPARc ligands alone.3.4. Determination of intracellular targets of 15d-PGJ2 in
NF-jB transcriptional pathway
Phosphorylation of IjBa, the inhibitory subunit of NF-jB
heterodimer on Ser-32 and Ser-36, is an important step in the
NF-jB activation process and is known to be mediated by the
IKKa=b complex. In order to identify potential targets of 15d-
PGJ2 in the NF-jB pathway, Western blots for phosphory-lated IjBa, IjBa and phosphorylated IKKa=b (Fig. 5A, B,
and C, respectively) were performed. IL-1b treatment strongly
induced the phosphorylation (Fig. 5A) and the degradation
(Fig. 5B) of IjBa ()80%, P < 0:05). Protein extracts from cells
pretreated with 15d-PGJ2 showed a partial inhibition ()55%,
P < 0:05) of IjBa degradation but did not aﬀect IL-1b-in-
duced IjBa phosphorylation. A pretreatment with Tro or Rosi
has no eﬀect on these parameters. Phosphorylation of IKKa=b
complex was induced by IL-1b treatment as shown in Fig. 5C.
If 15d-PGJ2 was shown to completely inhibit IL-1 b-induced
IKKb phosphorylation, we also observed an increase in IKKa
phosphorylation (+144%, P < 0:05). Troglitazone or Rosi pre-
treatment did not modulate IKKa=b phosphorylation induced
by IL-1b.4. Discussion
Anti-inﬂammatory eﬀects of PPARc ligands were highly
described in the literature. However, most of the studies de-
scribing their mechanism of action were performed on estab-
lished cell lines such as HeLa cells [22], cancer colorectal cell
lines [23], microglia cells [17] or macrophages [8]. Moreover,
signiﬁcant eﬀects with Tro and Rosi were obtained at high
concentrations (up to 100 lM), which are highly toxic for
chondrocytes. An important point of the present work is the
use of chondrocyte primary cultures, because cartilage is the
main tissue aﬀected in osteoarthritis pathology.
In a previous work, we have shown that 15d-PGJ2 was the
most eﬀective among PPARc ligands to modulate IL-1b action
Fig. 4. Eﬀect of PPARc ligands on the translocation of the p65 subunit in the nucleus (A) and on NF-jB activation (B) in IL-1b treated chon-
drocytes. Thirty-six hours after transfection with a PPARc expression vector, cells were pre-incubated with 10 lM PPARc ligands for 1 h before
being treated with IL-1b (10 ng/ml) for 30 min. (A) Nuclear protein extracts were prepared and 5 lg of nuclear extract was resolved on SDS/PAGE,
transferred to nitrocellulose membrane and probed with an antibody against p65. The gel shown is representative of three independent experiments.
(B) NF-jB activation was determined by ELISA kit (TransAm). Results are expressed as relative arbitrary units with a value of 100 for IL-1b
treatment and are representatives of three diﬀerent experiments.
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eﬀects of synthetic ligands was that the level of PPARc ex-
pression in chondrocytes would be too low. Since 15d-PGJ2
aﬃnity for its nuclear receptor is lower than Tro, this would
strongly suggest a PPARc-independent action of the cyclo-
pentenone.
To increase PPARc level in chondrocytes, overexpression of
PPARc in rat chondrocyte cultures was induced through
transient transfection experiments with an expression vector.
In transfected cultures, we observed that only 15d-PGJ2 was
able to decrease iNOS and COX-2 mRNA expression and NO
and PGE2 production induced by IL-1b. Taken together, these
results are very similar to those previously obtained in non-
transfected rat chondrocyte cultures. Thus, this strongly sug-
gests a main PPARc-independent action of 15d-PGJ2 in rat
chondrocytes.To further demonstrate that 15d-PGJ2 acts through a
PPARc-independent mechanism, we transfected chondrocytes
with a vector expressing a dominant negative form of PPARc.
The results clearly demonstrate that 15d-PGJ2 was still eﬀec-
tive to counteract IL-1b, by repressing iNOS and COX-2
mRNA. In the same way, the production of inﬂammatory
mediators was decreased. These results strengthen the hy-
pothesis that 15d-PGJ2 acts through a PPARc-independent
mechanism in rat chondrocytes.
NF-jB as well as AP-1 are transcriptional factors that
govern the expression of many genes involved in the devel-
opment of inﬂammatory processes [24–27] and in tissue deg-
radation [28]. Thus, these two transcriptional pathways have
been described as playing a central role in mediating the eﬀects
of IL-1b or TNFa in arthritic diseases and in cartilage deg-
radation [29,30]. NF-jB is activated after phosphorylation and
Fig. 5. 15d-PGJ2 did not aﬀect IL-1b-induced IjBa phosphorylation in rat chondrocytes but partially inhibited its degradation. Cells were incubated
1 h in the presence of PPARc ligands, then with 10 ng/ml IL-1b for 5 min. Total proteins were extracted and immunoblot analysis was performed
with speciﬁc antibodies. Total lysates were analyzed with antibodies against phosphorylated IjBa (A), non-phosphorylated IjBa (B), phosphory-
lated IKKa=b (C) and b-actin (D). The results shown are representative of three independent experiments.
S. Boyault et al. / FEBS Letters 572 (2004) 33–40 39degradation of the NF-jB inhibitor IjBa. IjBa is phosphor-
ylated by IKK complex, which contains two catalytic subunits
(IKKa and IKKb) at sites that trigger its ubiquitin-dependent
degradation [31].
In several recent publications, it has been demonstrated that
15d-PGJ2 could interfere with multiple steps in NF-jB sig-
nalling pathway. In activated murine macrophages, 15d-PGJ2
aﬀects IKK activity due to the inhibition of the phosphoryla-
tion of serine residues [15]. In the same way, Rossi et al. [16]
showed an inhibition of IKKb phosphorylation by 15d-PGJ2
in HeLa cells. However, to our knowledge, no data are
available concerning the mechanism by which 15d-PGJ2 acts in
chondrocytes, as well as putative intracellular target(s).
In the present work, we demonstrated that 15d-PGJ2, but
not synthetic ligands, inhibited the IL-1b-induced activation ofNF-jB transcriptional pathway. Interestingly, we also ob-
served that 15d-PGJ2 importantly inhibited IjBa degradation.
However, at the same time, this inhibition was not accompa-
nied by a decrease in phosphorylated IjBa level. This sur-
prising result suggests that 15d-PGJ2 could inhibit IjBa
protein degradation without aﬀecting its phosphorylation that
normally should trigger its ubiquitin-dependent degradation.
IjBa phosphorylation is the result of IKK complex activity.
We have then studied the eﬀects of a pre-treatment with 15d-
PGJ2 on both IKKa=b subunits enzymatic action. Our results
showed that only IL-1b-induced IKKb phosphorylation was
decreased but not IKKa phosphorylation. This would mean
that the phosphorylation of IjBa is the result of IKKa activ-
ity. According to the literature, IKKb phosphorylation trig-
gers the degradation of the inhibitory protein. Thus, we can
40 S. Boyault et al. / FEBS Letters 572 (2004) 33–40also suggest that the degradation of the inhibitory protein
through the proteasome pathway is inhibited as a result of the
absence of IKKb phosphorylation activity. To our knowledge,
this mechanism has not been described for cyclopentenone
prostaglandins in the literature, especially in chondrocytes.
Interestingly, a recent paper describing the eﬀects of epigallo-
catechin-3-gallate (EGCG), a green tea polyphenol [32,33],
reported a similar mechanism of action [34] in human chon-
drocytes. EGCG was shown to suppress IL-1b-induced IjBa
degradation but had no inhibitory eﬀect on the IjBa phos-
phorylating activity of IKK. However, the speciﬁc activities of
IKKa and IKKb subunits were not analyzed in this work.
Taken together, the results of the present work suggest a new
PPARc-independent inhibitory mechanism of NF-jB activa-
tion by 15d-PGJ2 in rat chondrocytes. The IjBa phosphory-
lating activity of IKKa is not decreased, indicating that the
inhibition of activation and translocation of NF-jB/p65 to the
nucleus may result from inhibition of the proteasome pathway.
This would then cause the stabilization and the accumulation
of IjBa in the cytoplasm of rat chondrocytes. In conclusion,
the anti-inﬂammatory eﬀects of 15d-PGJ2 seem to be mainly
PPARc-independent in IL-1b treated rat chondrocytes. These
new ﬁndings might help to understand new aspects of the anti-
inﬂammatory eﬀects of cyclopentenone prostaglandins, espe-
cially in chondrocytes.
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